Market Analysis

Market Assessment

The U.S. addressable spend for trauma-related nightmare treatment exceeds $5B annually. NightWare is positioned to capture scalable share in a fragmented market.

$5.2B
Direct Costs (U.S.)
27%
CAGR (2025-2030)
15M+
Total Patients

Growth Drivers

Rising PTSD Prevalence

Increasing diagnosis rates in both veteran and civilian populations.

RBD Expansion

New indication potential for REM Behavior Disorder (1-2% of seniors).

Global Licensing

Strategic expansion opportunities in Israel, EU, and APAC markets.

Strategic Analysis

Strengths

  • Only FDA-cleared therapy
  • Real-world clinical data
  • Proprietary AI IP

Opportunities

  • Custom hardware development
  • SaaS revenue models
  • Expansion to RBD

Risks

  • Reimbursement adoption speed
  • Competitive entry (long-term)
  • Supply chain reliance

Download Full Report

Get the complete Market Assessment PDF with detailed breakdown of tailwinds, headwinds, and strategic recommendations.